Core Viewpoint - Needham analyst Ami Fadia has raised the price target for Jazz Pharmaceuticals (JAZZ) to $235 from $210 while maintaining a Buy rating on the shares, indicating positive sentiment towards the company's future performance [1]. Group 1: Study Insights - The company presented the HERIZON-GEA-01 study with additional details on subgroup analysis, showing that overall data favored zani treatment arms across all subgroups [1]. - The study indicated a longer progression-free survival (PFS) for the tislelizumab arm and slightly higher efficacy in TAP under 1% compared to TAP at 1% or higher [1]. Group 2: Expert Opinions - A key opinion leader noted that the benefits demonstrated by zani are "practice-changing," suggesting that zanidatamab plus chemotherapy with tislelizumab is expected to quickly replace the current standard of care [1].